Why Standard Flu Vaccines Won’t Make Investors Rich
May 5th, 2009 | By Patrick Cox | Category: Featured, Technology
A more recent addition to my transformational technologies portfolio, Medarex, has scored a huge win. The company, along with Massachusetts Biologic Laboratory, will get $60 million upfront from Merck for license rights to a monoclonal antibody that apparently cures C. difficile infection. They are eligible for another $165 million in ...read more
